Weekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial

Simple item page
dc.contributor.authorReyes, Maria Loreto
dc.contributor.authorVizcaya, Cecilia
dc.contributor.authorLe Roy, Catalina
dc.contributor.authorLoureiro, Carolina
dc.contributor.authorBrinkmann, Karin
dc.contributor.authorCampos, Laura
dc.contributor.authorArancibia, Monica
dc.contributor.authorIturriaga, Carolina
dc.contributor.authorPerez-Mateluna, Guillermo
dc.contributor.authorRojas-McKenzie, Maite
dc.contributor.authorDominguez, Gonzalo
dc.contributor.authorCamargo Jr, Carlos A.
dc.contributor.authorBorzutzky, Arturo
dc.date.accessioned2025-01-20T16:08:22Z
dc.date.available2025-01-20T16:08:22Z
dc.date.issued2024
dc.description.abstractObjective: To evaluate the effectiveness of weekly vitamin D supplementation in reducing the number of acute respiratory infections (ARI) in preschool children. Study design: Randomized, double-blind, placebo-controlled trial in 303 children aged 1.5-3.5 years from 2014 to 2105 in 3 Chilean cities at different latitudes: Santiago (33 degrees S, n = 101), Talcahuano (37 degrees S, n = 103), and Punta Arenas (53 degrees S, n = 99). Participants were allocated (1:1:1) to receive placebo, cholecalciferol (vitamin D3 (VD3)) 5600 IU/week (low-dose), or 11 200 IU/week (high-dose) for 6 months. Primary outcome was parent-reported number of ARI; secondary outcomes included number of ARI hospitalizations, change of serum 25-hydroxyvitamin D (25(OH)D) and LL-37/cathelicidin levels, and adverse events. Results: The mean age of participants was 26 +/- 6 months; 45% were female. Baseline 25(OH)D was 24.9 +/- 6.1 ng/ml, with 23% having 25(OH)D <20 ng/ml. No significant baseline clinical or laboratory differences were observed among groups. Overall, 64% (n = 194) completed study participation, without baseline differences between subjects lost to follow-up vs those completing participation or differences in completion rates across groups. After 6 months, a dose-dependent increase in serum 25(OH)D was observed from the VD3 intervention (P < .001), with a higher proportion of subjects ending the trial with 25(OH)D <20 ng/ml in the placebo group (30.8%) vs the low-dose (7.4%) and high-dose groups (5.1%). However, no group differences were observed in number of ARI (P = .85), ARI hospitalizations (P = .20), LL-37/cathelicidin change (P = .30), or adverse events (P = .41). Conclusions: While weekly VD3 supplementation, in doses equivalent to 800 IU and 1600 IU daily, was associated with improved 25(OH)D levels in preschoolers, we did not find a reduced number of ARI in this sample.
dc.description.funderFondo Nacional de Investigacion y Desarrollo en Salud
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.jpeds.2024.114249
dc.identifier.eissn1097-6833
dc.identifier.issn0022-3476
dc.identifier.urihttps://doi.org/10.1016/j.jpeds.2024.114249
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90072
dc.identifier.wosidWOS:001315508200001
dc.language.isoen
dc.revistaJournal of pediatrics
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleWeekly Vitamin D Supplementation to Prevent Acute Respiratory Infections in Young Children at Different Latitudes: A Randomized Controlled Trial
dc.typeartículo
dc.volumen275
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas